Abigail Brooks, MA

The Holly system is a first-of-its-kind implantable, continuous dialysis system designed to give patients freedom from the cycle of center-based dialysis.

Findings from the CARE feasibility RCT show the safety, feasibility, and likely cost-effectiveness of intentional weight loss before colorectal cancer surgery.

The approval makes inebilizumab-cdon the first and only CD19-targeted B cell therapy indicated for anti-AChR and anti-MuSK Ab+ generalized myasthenia gravis.

The approval of a dye- and preservative-free powder formulation of trofinetide offers a new option for adult and pediatric patients with Rett syndrome.

Historic progress in renal xenotransplantation in 2025 brings pig kidney transplants closer to clinical reality amid an ongoing donor organ shortage.

The approval makes etuvetidigene autotemcel (Waskyra) the first cell-based gene therapy for the treatment of Wiskott-Aldrich syndrome.

The approval of Ayrmid’s omidubicel-onlv makes it the first hematopoietic stem cell transplant therapy to treat patients with severe aplastic anemia.

The 8-3 APIC vote recommends individual-based decision-making for HBV vaccination in infants born to women who test negative for the virus.

Catch up on new AASLD MASH guidelines on semaglutide, key research from The Liver Meeting 2025, and more.

The accelerated approval expands Avance use to motor, mixed, and long-gap sensory nerve injuries, with required confirmatory trials to verify clinical benefit.

Catch up on GI FDA news, new American Gastroenterological Association Crohn’s disease guidelines, and more gastroenterology updates from November.

State- and local-level disparities in the availability of gastroenterologist care disproportionately affect patients with IBD and populations living in rural and high-poverty areas.

Study findings suggest ChatGPT and Gemini both require further model improvements before relying solely on LLMs in clinical nutrition practice.

Children with MASLD were more likely to live in neighborhoods with greater socioeconomic and environmental disadvantage than those with overweight or obesity but without MASLD.

The living guideline incorporates new medications and the latest data to make recommendations for moderate-to-severely active CD care.

The analysis of data from a single-source rare disease specialty pharmacy sheds light on high treatment adherence and low discontinuation of Cuvrior.

Findings showed elafibranor led to expression changes of proteins linked to fatigue or mitochondrial function, significantly correlated with each other and with fatigue improvement.

Findings suggest AOOS in liver transplantation is widespread across the US and benefits a small subset of centers, undermining equity and transparency in allocation.

A post hoc analysis of the phase 2b SYMMETRY trial highlights efruxifermin’s impact on overall fibrosis burden and septa area.

The new guidance seeks to aid patient selection, comorbidity management, and monitoring the safety and effectiveness of semaglutide for MASH.

Findings support a sex-specific approach to MetALD and ALD definitions and the need to incorporate binge drinking frequency into clinical risk stratification.

The decision makes linaclotide (Linzess) capsules the first FDA-approved treatment for pediatric patients 7 years and older with irritable bowel syndrome with constipation.

View slated expert interviews and 5 clinical trials to watch at AASLD The Liver Meeting 2025.

Check out the latest GI FDA news, new trial data in IBD, headlines from ACG 2025, and more.

Check out the latest episode of Liver Lineup on alcohol-associated liver disease, new data on resmetirom, hepatic headlines from ACG 2025, and more.

Markov model findings showed elafibranor provided greater health benefit at a lower cost than seladelpar in ursodeoxycholic acid incomplete responders.

Real-world data suggest adding fibrates to first-line UDCA incurs several clinical benefits, including reductions in spontaneous bacterial peritonitis and hospitalizations.

Despite bearing a greater obesity burden, Black, Hispanic, and American Indian/Native individuals are underrepresented in GLP-1 RA RCTs for weight loss.

Findings from a prespecified analysis of the phase 3 MAESTRO-NASH trial highlight resmetirom’s consistent benefit with background SGLT2i or GLP-1 RA treatment.

Findings suggest having GERD incurs an 18% greater risk of a new AUD diagnosis, presenting an opportunity to discuss alcohol use with patients.